Osaka, Osaka Prefecture, Japan Dainippon Sumitomo Pharma is the famous Corporate Investor, which was founded in 1997. The fund was located in Asia if to be more exact in Japan. The leading representative office of defined Corporate Investor is situated in the Osaka.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Dainippon Sumitomo Pharma, startups are often financed by WERU Investment, SMBC Venture Capital, Real Tech Fund. The meaningful sponsors for the fund in investment in the same round are tella, Shin Nippon Biomedical Laboratories (SNBL), Nikon.
Among the most successful fund investment fields, there are Health Care, Biotechnology. The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Edison Pharmaceuticals, Meltin MMI, Healios K.K. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Japan.
The real fund results show that this Corporate Investor is 47 percentage points more often commits exit comparing to other companies. The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2015. The usual things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Dainippon Sumitomo Pharma performs on 4 percentage points more the average number of lead investments.
Related Funds
| Fund Name | Location |
| Diehl Ventures | Bayern, Germany, Nuremberg |
| eCatalogs | California, Los Angeles, United States |
| Foresight 4 VCT plc | - |
| GlobalNetFinancial | Boca Raton, Florida, United States |
| Hankang Capital | China, Shanghai |
| Security Pacific National Bank | California, Los Angeles, United States |
| WFD Ventures | New York, New York, United States |
| Wolverine Trading | Chicago, Illinois, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
AlphaNavi Pharma | $8M | 05 Apr 2019 | Kyoto Prefecture | ||
Meltin MMI | $18M | 17 Oct 2018 | Chiyoda, Japan |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
AlphaNavi Pharma | $8M | 05 Apr 2019 | Kyoto Prefecture | ||
Meltin MMI | $18M | 17 Oct 2018 | Chiyoda, Japan |
